Prenatal identification of trisomy 18 (Edwards syndrome)
View/ Open
PALOMAKIPrenatalIdentification2011.pdf
Embargoed until: 3333-01-01
Reason: EM1914
Embargoed until: 3333-01-01
Reason: EM1914
Metadata
Show full item recordAbstract
This thesis is a critical literature review of trisomy 18 (Edwards syndrome), focused on
maternal serum and ultrasound markers between 10 and 20 weeks’ gestation. Based on
comprehensive meta-analyses, existing findings are clarified, new knowledge has emerged,
and novel statistical modeling demonstrates clinically useful algorithms to guide screening
policies.
Trisomy 18 is, after Down syndrome, the autosomal aneuploidy with the highest birth
prevalence, about 2.4/10,000. Only 1 in 5 live born survives to two weeks, with 1 in 20
surviving one year. Strategies for identifying trisomy 18 in early pregnancy rely on reinterpretation
of markers measured as part of Down syndrome screening. Diagnosis
requires collecting fetal or placental material obtained from an invasive procedure
(amniocentesis or a chorionic villus sampling) and subsequent karyotyping or specific
aneuploidy testing such as fluorescent in situ hybridization.
The second trimester Triple Test (serum markers alpha-fetoprotein, unconjugated estriol
and human chorionic gonadotropin [hCG]) has an 81% detection rate at a 0.4% false
positive rate. Adding pregnancy-associated plasma protein-A (PAPP-A) is effective; the
detection rate improves to 88% while false positives are reduced to 0.1%. In the first
trimester Combined Test, the serum markers (free β hCG and PAPP) in combination with
unbiased estimates of ultrasound marker nuchal translucency (NT) thickness, yields
detection and false positive rates of 86% and 0.2%, respectively. For these tests, hCG and
free β hCG measurements are essentially interchangeable. Combining existing markers
from both trimesters into a Full Integrated Test (NT, PAPP-A, and the Triple Test), also
yields high performance (91% detection rate at 0.2% false positive rate). Ultrasound
markers, apart from NT, are not suitable for routine practice, but some could be used in
specialist centers. In the future, testing of circulating cell free nucleic acids in maternal
plasma may allow for a reduction in the use of invasive procedures.
Authors
Palomaki, Glenn EricCollections
- Theses [3366]